-
Je něco špatně v tomto záznamu ?
Effect of Overweight and Obesity on the Response to Anti-TNF Therapy and Disease Course in Children With IBD
S. Sila, M. Aloi, U. Cucinotta, L. Gianolio, M. Granot, O. Hradsky, S. Hussey, B. Kang, A. Karoliny, KL. Kolho, J. de Laffolie, S. Lega, M. Matar, L. Norsa, S. Omiwole, E. Orlanski-Meyer, L. Palomino, P. Rohani, L. Scarallo, M. Sladek, MH....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
PubMed
39083286
DOI
10.1093/ibd/izae165
Knihovny.cz E-zdroje
- MeSH
- dítě MeSH
- idiopatické střevní záněty * farmakoterapie komplikace MeSH
- infliximab terapeutické užití MeSH
- lidé MeSH
- mladiství MeSH
- nadváha * komplikace MeSH
- následné studie MeSH
- obezita * komplikace MeSH
- recidiva MeSH
- retrospektivní studie MeSH
- rizikové faktory MeSH
- TNF-alfa * antagonisté a inhibitory MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
BACKGROUND: This study aimed to evaluate the effect of overweight and obesity at the start of anti-TNF therapy on treatment response and relapse rate in children with inflammatory bowel disease (IBD). METHODS: This multicenter, retrospective cohort study included 22 IBD centers in 14 countries. Children diagnosed with IBD in whom antitumor necrosis factor (anti-TNF) was introduced were included; those who were overweight/obese were compared with children who were well/undernourished. RESULTS: Six hundred thirty-seven children (370 [58%] males; mean age 11.5 ± 3.5 years) were included; 140 (22%) were in the overweight/obese group (OG) and 497 (78%) had BMI ≤1 SD (CG). The mean follow-up time was 141 ± 78 weeks (median 117 weeks). There was no difference in the loss of response (LOR) to anti-TNF between groups throughout the follow-up. However, children in OG had more dose escalations than controls. Male sex and lack of concomitant immunomodulators at the start of anti-TNF were risk factors associated with the LOR. There was no difference in the relapse rate in the first year after anti-TNF introduction; however, at the end of the follow-up, the relapse rate was significantly higher in the OG compared with CG (89 [64%] vs 218 [44%], respectively, P < .001). Univariate and multivariate analysis revealed that being overweight/obese, having UC, or being of male sex were factors associated with a higher risk for relapse. CONCLUSIONS: Overweight/obese children with IBD were not at a higher risk of LOR to anti-TNF. Relapse in the first year after anti-TNF was introduced, but risk for relapse was increased at the end of follow-up.
Children's Hospital Zagreb University of Zagreb Medical School Zagreb Croatia
Department of Pediatrics School of Medicine Kyungpook National University Daegu Korea
DOCHAS Group Children's Health Ireland University College Dublin Dublin Ireland
Gastroenterology and Nutrition Unit Hospital Infantil Universitario Niño Jesús Madrid Spain
Gastroenterology and Nutrition Unit Meyer Children Hospital IRCCS Florence Italy
Heim Pal National Pediatric Institute Budapest Hungary
Institute for Maternal and Child Health IRCCS Burlo Garofolo Trieste Italy
Justus Liebig University Giessen Childrens Hospital Giessen Germany
Pediatric Department Children's Hospital Vittore Buzzi University of Milan Milan Italy
Pediatric Gastroenterology Unit Sapienza University Umberto 1 Hospital Rome Italy
University of Helsinki and Children ́s Hospital HUS HelsinkiFinland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015757
- 003
- CZ-PrNML
- 005
- 20250731091219.0
- 007
- ta
- 008
- 250708s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/ibd/izae165 $2 doi
- 035 __
- $a (PubMed)39083286
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Sila, Sara $u Children's Hospital Zagreb, University of Zagreb Medical School, Zagreb, Croatia
- 245 10
- $a Effect of Overweight and Obesity on the Response to Anti-TNF Therapy and Disease Course in Children With IBD / $c S. Sila, M. Aloi, U. Cucinotta, L. Gianolio, M. Granot, O. Hradsky, S. Hussey, B. Kang, A. Karoliny, KL. Kolho, J. de Laffolie, S. Lega, M. Matar, L. Norsa, S. Omiwole, E. Orlanski-Meyer, L. Palomino, P. Rohani, L. Scarallo, M. Sladek, MH. Sohouli, D. Urlep, A. Yerushalmy-Feler, E. Zifman, I. Hojsak
- 520 9_
- $a BACKGROUND: This study aimed to evaluate the effect of overweight and obesity at the start of anti-TNF therapy on treatment response and relapse rate in children with inflammatory bowel disease (IBD). METHODS: This multicenter, retrospective cohort study included 22 IBD centers in 14 countries. Children diagnosed with IBD in whom antitumor necrosis factor (anti-TNF) was introduced were included; those who were overweight/obese were compared with children who were well/undernourished. RESULTS: Six hundred thirty-seven children (370 [58%] males; mean age 11.5 ± 3.5 years) were included; 140 (22%) were in the overweight/obese group (OG) and 497 (78%) had BMI ≤1 SD (CG). The mean follow-up time was 141 ± 78 weeks (median 117 weeks). There was no difference in the loss of response (LOR) to anti-TNF between groups throughout the follow-up. However, children in OG had more dose escalations than controls. Male sex and lack of concomitant immunomodulators at the start of anti-TNF were risk factors associated with the LOR. There was no difference in the relapse rate in the first year after anti-TNF introduction; however, at the end of the follow-up, the relapse rate was significantly higher in the OG compared with CG (89 [64%] vs 218 [44%], respectively, P < .001). Univariate and multivariate analysis revealed that being overweight/obese, having UC, or being of male sex were factors associated with a higher risk for relapse. CONCLUSIONS: Overweight/obese children with IBD were not at a higher risk of LOR to anti-TNF. Relapse in the first year after anti-TNF was introduced, but risk for relapse was increased at the end of follow-up.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a TNF-alfa $x antagonisté a inhibitory $7 D014409
- 650 _2
- $a mladiství $7 D000293
- 650 12
- $a nadváha $x komplikace $7 D050177
- 650 12
- $a idiopatické střevní záněty $x farmakoterapie $x komplikace $7 D015212
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a následné studie $7 D005500
- 650 12
- $a obezita $x komplikace $7 D009765
- 650 _2
- $a infliximab $x terapeutické užití $7 D000069285
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Aloi, Marina $u Pediatric Gastroenterology Unit, Sapienza University-Umberto I Hospital, Rome, Italy $1 https://orcid.org/0000000174122279
- 700 1_
- $a Cucinotta, Ugo $u Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood, University of Messina, Italy
- 700 1_
- $a Gianolio, Laura $u Department of Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children and Young People, Edinburgh, UK
- 700 1_
- $a Granot, Maya $u Pediatric Gastroenterology and Nutrition Unit, Sheba Medical Center, Tel-HaShomer, The Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- 700 1_
- $a Hradsky, Ondrej $u Department of Paediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Hussey, Séamus $u DOCHAS Group, Children's Health Ireland, University College Dublin, Dublin, Ireland
- 700 1_
- $a Kang, Ben $u Department of Pediatrics, School of Medicine, Kyungpook National University, Daegu, Korea $1 https://orcid.org/0000000285169803
- 700 1_
- $a Karoliny, Anna $u Heim Pal National Pediatric Institute, Budapest, Hungary
- 700 1_
- $a Kolho, Kaija-Leena $u University of Helsinki and Children ́s Hospital, HUS, HelsinkiFinland $1 https://orcid.org/0000000191708415
- 700 1_
- $a de Laffolie, Jan $u Justus-Liebig-University Giessen, Childrens Hospital, Giessen, Germany
- 700 1_
- $a Lega, Sara $u Institute for Maternal and Child Health, IRCCS "Burlo Garofolo," Trieste, Italy
- 700 1_
- $a Matar, Manar $u Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Centre, Petach-Tikva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- 700 1_
- $a Norsa, Lorenzo $u Pediatric Hepatology, Gastroenterology and Transplantation Department, ASST Papa Giovanni XXIII, Bergamo, Italy $u Pediatric Department, Children's Hospital Vittore Buzzi, University of Milan, Milan, Italy $1 https://orcid.org/0000000333222921
- 700 1_
- $a Omiwole, Sharon $u DOCHAS Group, Children's Health Ireland, University College Dublin, Dublin, Ireland
- 700 1_
- $a Orlanski-Meyer, Esther $u Juliet Keidan Institute of Pediatric Gastroenterology, Hepatology, and Nutrition, Shaare Zedek Medical Center, the Hebrew University of Jerusalem, Jerusalem, Israel
- 700 1_
- $a Palomino, Laura $u Gastroenterology and Nutrition Unit, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
- 700 1_
- $a Rohani, Pejman $u Pediatric Gastroenterology and Hepatology Research Center, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
- 700 1_
- $a Scarallo, Luca $u Gastroenterology and Nutrition Unit, Meyer Children Hospital IRCCS, Florence, Italy
- 700 1_
- $a Sladek, Margaret $u Department of Pediatrics, Gastroenterology and Nutrition Jagiellonian University Medical College, Kracow, Poland
- 700 1_
- $a Sohouli, Mohammad Hassan $u Pediatric Gastroenterology and Hepatology Research Center, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
- 700 1_
- $a Urlep, Darja $u Pediatric Gastroenterology and Liver Unit, University Children's Hospital of the University Medical Centre Ljubljana, Ljubljana, Slovenia $1 https://orcid.org/000000027297538X
- 700 1_
- $a Yerushalmy-Feler, Anat $u Pediatric Gastroenterology Institute, Tel Aviv Sourasky Medical Center and the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- 700 1_
- $a Zifman, Eyal $u Pediatric gastroenterology clinic, Meir Medical Center, Kfar Saba and School of Medicine, Tel-Aviv University, Tel Aviv, Israel
- 700 1_
- $a Hojsak, Iva $u Children's Hospital Zagreb, University of Zagreb Medical School, Zagreb, Croatia $1 https://orcid.org/0000000332625964
- 773 0_
- $w MED00002243 $t Inflammatory bowel diseases $x 1536-4844 $g Roč. 31, č. 5 (2025), s. 1263-1271
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39083286 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091213 $b ABA008
- 999 __
- $a ok $b bmc $g 2366538 $s 1252882
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 31 $c 5 $d 1263-1271 $e 20250512 $i 1536-4844 $m Inflammatory bowel diseases $n Inflamm Bowel Dis $x MED00002243
- LZP __
- $a Pubmed-20250708
